Opposed evolution of the osseous and soft parts of progestin-associated osteomeningioma after progestin intake discontinuation
OBJECTIVE: Numerous studies have confirmed a strong association between progestins and meningiomas and the regression and/or stabilization of meningiomas after discontinuation of treatment. Osteomeningiomas represent a small subgroup of meningiomas that appear to be more common among progestin-related meningiomas. However, the specificity of the behavior of this subset of meningiomas after discontinuation of progestin has not yet been assessed.
METHODS: Thirty-six patients (mean age 49.5 years) who presented with at least one progestin-related osteomeningioma (48 tumors total) were identified from a prospectively collected database of patients and had been referred to our department for meningioma and had documented use of cyproterone acetate, nomegestrol acetate, and/or chlormadinone acetate. Hormonal treatment was stopped at the time of diagnosis for all the patients, and the clinical and radiological evolution of this subgroup of tumors was evaluated.
RESULTS: For half of the 36 patients, treatment was prescribed for signs of hyperandrogenism, such as hirsutism, alopecia, or acne. Most lesions were spheno-orbital (35.4%) or frontal (31.2%). Although the tissular part of the meningioma shrank in 77.1% of cases, the osseous part exhibited discordant behavior with 81.3% showing volume progression. The combination of estrogens, as well as the prolonged duration of progestin treatment, seems to increase the risk of progression of the osseous part after treatment discontinuation (p = 0.02 and p = 0.028, respectively). No patient required surgical treatment at diagnosis or during the study.
CONCLUSIONS: These results show that while the soft intracranial part of progestin-related osteomeningioma tumor is the most likely to regress after treatment discontinuation, the bony part is more likely to increase in volume. These findings suggest the need for careful follow-up of these patients, especially those with tumors near the optical apparatus.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:139 |
|---|---|
| Enthalten in: |
Journal of neurosurgery - 139(2023), 4 vom: 01. Okt., Seite 944-952 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Florea, Simona M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4KM2BN5JHF |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 27.10.2023 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.3171/2022.12.JNS222006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353894184 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353894184 | ||
| 003 | DE-627 | ||
| 005 | 20231226061044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3171/2022.12.JNS222006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353894184 | ||
| 035 | |a (NLM)36883659 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Florea, Simona M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Opposed evolution of the osseous and soft parts of progestin-associated osteomeningioma after progestin intake discontinuation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 27.10.2023 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: Numerous studies have confirmed a strong association between progestins and meningiomas and the regression and/or stabilization of meningiomas after discontinuation of treatment. Osteomeningiomas represent a small subgroup of meningiomas that appear to be more common among progestin-related meningiomas. However, the specificity of the behavior of this subset of meningiomas after discontinuation of progestin has not yet been assessed | ||
| 520 | |a METHODS: Thirty-six patients (mean age 49.5 years) who presented with at least one progestin-related osteomeningioma (48 tumors total) were identified from a prospectively collected database of patients and had been referred to our department for meningioma and had documented use of cyproterone acetate, nomegestrol acetate, and/or chlormadinone acetate. Hormonal treatment was stopped at the time of diagnosis for all the patients, and the clinical and radiological evolution of this subgroup of tumors was evaluated | ||
| 520 | |a RESULTS: For half of the 36 patients, treatment was prescribed for signs of hyperandrogenism, such as hirsutism, alopecia, or acne. Most lesions were spheno-orbital (35.4%) or frontal (31.2%). Although the tissular part of the meningioma shrank in 77.1% of cases, the osseous part exhibited discordant behavior with 81.3% showing volume progression. The combination of estrogens, as well as the prolonged duration of progestin treatment, seems to increase the risk of progression of the osseous part after treatment discontinuation (p = 0.02 and p = 0.028, respectively). No patient required surgical treatment at diagnosis or during the study | ||
| 520 | |a CONCLUSIONS: These results show that while the soft intracranial part of progestin-related osteomeningioma tumor is the most likely to regress after treatment discontinuation, the bony part is more likely to increase in volume. These findings suggest the need for careful follow-up of these patients, especially those with tumors near the optical apparatus | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chlormadinone acetate | |
| 650 | 4 | |a cyproterone acetate | |
| 650 | 4 | |a nomegestrol acetate | |
| 650 | 4 | |a oncology | |
| 650 | 4 | |a osteomeningioma | |
| 650 | 4 | |a primary intraosseous meningioma | |
| 650 | 4 | |a progestin | |
| 650 | 4 | |a tumor | |
| 650 | 7 | |a Progestins |2 NLM | |
| 650 | 7 | |a Cyproterone Acetate |2 NLM | |
| 650 | 7 | |a 4KM2BN5JHF |2 NLM | |
| 700 | 1 | |a Passeri, Thibault |e verfasserin |4 aut | |
| 700 | 1 | |a Abbritti, Rosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Bernat, Anne L |e verfasserin |4 aut | |
| 700 | 1 | |a Fontanel, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Yoldjian, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Funck-Brentano, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Weill, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Mandonnet, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Froelich, Sébastien |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neurosurgery |d 1945 |g 139(2023), 4 vom: 01. Okt., Seite 944-952 |w (DE-627)NLM000006254 |x 1933-0693 |7 nnns |
| 773 | 1 | 8 | |g volume:139 |g year:2023 |g number:4 |g day:01 |g month:10 |g pages:944-952 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3171/2022.12.JNS222006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 139 |j 2023 |e 4 |b 01 |c 10 |h 944-952 | ||